A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes,
can decrease or affect the ability of breast cancer cells to grow and whether Metformin will
work with other therapies to keep cancer from recurring. Health Canada has not approved the
sale or use of Metformin to treat breast cancer, although they have approved its use in this
clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its
use in breast cancer is considered investigational.
Phase:
Phase 3
Details
Lead Sponsor:
Canadian Cancer Trials Group NCIC Clinical Trials Group
Collaborators:
ICR-CTSU International Breast Cancer Study Group National Cancer Institute (NCI)